Dana-Farber Cancer Institute collaborates with a variety of hospitals and research institutions to provide our patients with the best possible cancer care.
The Dana-Farber/Brigham and Women's Cancer Center is a collaboration between Dana-Farber Cancer Institute and Brigham and Women's Hospital to care for adults with cancer. Dana-Farber provides outpatient services, while inpatient care is provided by Brigham and Women's Hospital.
The Dana-Farber/Brigham and Women's Cancer Center cares for adult patients in 13 specialized centers, each devoted to helping people fight a different type of cancer. The specialists in each center work as a team to provide expert evaluation and care. This coordinated arrangement makes it possible for many patients to meet with a number of specialists in a single visit.
Through a long-standing collaboration between Dana-Farber Cancer Institute and, Boston Children's Hospital outpatient care for children is provided at Dana-Farber's Jimmy Fund Clinic while neighboring Children's Hospital offers inpatient care and pediatric subspecialty consultation. The two institutions function as one to provide a seamless care experience for children with cancer.
The Jimmy Fund Clinic is specifically designed for the comfort and convenience of children with cancer and their families in an outpatient setting. It has a playroom for young children, a separate activities room for teens, spacious exam and procedures rooms, and separate chemotherapy rooms for young children and teens. Private chemotherapy rooms are available for patients at high risk of infection.
Three units at Boston Children's Hospital are dedicated to the inpatient care of children with cancer. A patient activity room is available for young children and teens. Surgery and diagnostic imaging, such as MRI and CT scans, are also provided at Children's Hospital.
In 1996, Dana-Farber Cancer Institute and the founding members of Partners Healthcare System (Brigham and Women's Hospital and Massachusetts General Hospital) consolidated their adult oncology programs and clinical research under Dana-Farber/Partners Cancer Care. Today, the three Dana-Farber/Partners Cancer Care hospitals serve more than 12,000 new cancer patients annually and comprise the largest cancer-care system in the United States.
Patient care is provided at the combined campuses of Dana-Farber/Brigham and Women's Hospital in Boston's Longwood Medical Area, and at Massachusetts General Hospital in downtown Boston.
At the Dana-Farber/Brigham and Women's campus, patients receive outpatient care at Dana-Farber and inpatient care across the street at Brigham and Women's Hospital. Patients are cared for by the same group of physicians in both settings. At Massachusetts General Hospital, patients receive outpatient services in the Cancer Center and inpatient services in the adjoining hospital.
Regardless of which campus patients select, they receive the highest standard of care from some of the nation's leading cancer specialists, and have access to the same innovative treatments offering the best possible outcomes.
In an effort to better harness the research resources of Harvard University to fight cancer, Dana-Farber Cancer Institute has joined with Harvard School of Public Health, Harvard Medical School, and four of its affiliated hospitals to create the Dana-Farber/Harvard Cancer Center (DF/HCC).
The institutions – which include Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Boston Children's Hospital, and Massachusetts General Hospital – collaborate on clinical and basic research, cancer prevention, and new treatments and therapies to provide better outcomes for cancer patients.
DF/HCC's researchers, who number more than 1000, have access to 18 core facilities, many of which are large laboratories with equipment and facilities that are generally too expensive for any one researcher, or often, any one institution, to invest in alone. A large series of collaborative programs are organized around research on specific diseases (such as breast, gynecologic, leukemia, lymphoma, and prostate cancer). Other programs are structured by research disciplines, such as biostatistics, cancer immunology, outcomes research, and experimental therapeutics.
Dana-Farber Cancer Institute's designation by the National Cancer Institute as comprehensive cancer center was expanded to include the entire DF/HCC in 2000.
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: